| A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD) (NCT07586306) | Shanghai Vitalgen BioPharma Co., Ltd. | 2026-06-01 |
| A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations (NCT07414290) | Shanghai Vitalgen BioPharma Co., Ltd. | 2026-05-25 |
| A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease (NCT07603050) | Shanghai Vitalgen BioPharma Co., Ltd. | 2026-05-14 |
| Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy (NCT06699108) | Shanghai Vitalgen BioPharma Co., Ltd. | 2024-12-13 |
| A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease (NCT06480461) | Shanghai Vitalgen BioPharma Co., Ltd. | 2024-09-02 |
| A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency (NCT06432140) | Shanghai Vitalgen BioPharma Co., Ltd. | 2024-07-02 |
| A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b (NCT06217861) | Shanghai Vitalgen BioPharma Co., Ltd. | 2024-04-29 |
| Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy (NCT05694598) | Shanghai Vitalgen BioPharma Co., Ltd. | 2023-03-27 |
| Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study (NCT05442528) | Shanghai Vitalgen BioPharma Co., Ltd. | 2022-08-01 |
| A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients (NCT05441553) | Shanghai Vitalgen BioPharma Co., Ltd. | 2022-07-01 |